Announced Fri, 31 Jul · 18:05 IST
SMS Pharma Q1 PAT up 16% YoY at Rs 21.13 cr; Rs 50 cr loan to subsidiary
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.9%1-day move
₹374.50
prior close
₹375.75
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.8-1.7-2.1-2.0-2.9-2.9-4.5+1.2+0.4-0.1-5.5-0.1——
Up moveDown movePending
AI summary
SMS Pharma Q1 FY26-27 standalone revenue rose 5.6% YoY to Rs 206.96 cr; PAT up 16% at Rs 21.13 cr vs Rs 18.21 cr. Consolidated PAT at Rs 20.91 cr. Board fixed Sep 16 as record date for FY26 dividend, AGM on Sep 23. Approved loan of up to Rs 50 cr to subsidiary SMS Peptides. Re-appointed MD for 5 years.
Likely market impact
Modest revenue growth with strong PAT growth signals operational efficiency. Dividend record date set. Subsidiary loan needs shareholder approval.